[{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Dialco Medical"}]

Find Clinical Drug Pipeline Developments & Deals for Sulfate, Polymyxin B

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 04, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 05, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Paradigm Capital

                          Deal Size : $6.2 million

                          Deal Type : Financing

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Paradigm Capital

                          Deal Size : $8.5 million

                          Deal Type : Financing

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : $5.0 million

                          February 21, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Baxter Healthcare Corporation

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 14, 2023

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 08, 2023

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Paradigm Capital

                          Deal Size : $3.7 million

                          Deal Type : Private Placement

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details :

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Dialco Medical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank